BIONCISE
ActiveFrom the official registers: KBO 8 annual accounts at the National Bank publications in the Belgian Official Gazette
Summary
BIONCISE has been active since 2017 and the Belgian Official Gazette contains no insolvency or warning signals. The 2025 annual accounts show equity of €172,478 and a net result of -€29,476. Equity is shrinking by about 3.1% per year across the filed financial years. Its solvency ranks better than 79% of 274 sector peers (NACE 32, financial year 2025). The computed 12-month bankruptcy probability is 0.6% (low).
Overview
Official details
KBO- Status
- Active since 02-03-2017 Normal situation
- Legal form
- Public limited company
- Registered office
- Bodemstraat 16, 3830 Wellen
- Activity
- Manufacture of medical and dental instruments and supplies NACE 32500and 3 others
- Establishment unit
- 2.262.452.150 3830 Wellen, since 02-03-2017
- Financial year end
- 31 December
- Peppol
- Reachable since 07-01-2026
Who decides
Board
- JANSSENS Jacques PhilibertManaging director
- BUTTIENS Magda Jeanne JoséeDirector
- JANSSENS JohanDirector
Shareholders
How it is doing
- Bankruptcy probabilitywithin 12 months
- 0.6%
Annual accounts 2025
- Gross margin
- €125,449
- ▼ 23.5%
- Turnover
- ≈ €320,000
- estimated
- Loss
- €29,476
- Equity
- €172,478
- ▼ 14.6%
- Total assets
- €242,768
- ▼ 8.9%
- Staff
- 2 FTE
- =
2025 accounts 18 days early
Filed on 13-07-2026at the National Bank
Why 70raises riskLoss of €29,476 (financial year 2025)1 change of registered office in 24 months1 of the last 3 latelowers riskLiquidity: current ratio 2.82, cash €68,841Show the evidence
Checked score
Score 2025
70
/ 100
Healthy
Probability in this band: 0.55% to 1.5%
Financially better than 48% of its sector peers (NACE 32, micro)
Financial strength · tick = 2024
Strong
Solvency
96-4
equity 71.0% of total assets
Liquidity
74+13
short-term debt 27.6% · cash 28.4%
Profitability
14-67
return on assets -12.1%
Bankruptcy probability, 12 months
0.6%
Low
0%0.5%1.5%4%10%≥ 25%
About 6 in 1,000 comparable companies go bankrupt within 12 months (an estimate).
Last 24 months
11-2024: 0.9%
12-2024: 0.9%● unchanged vs 11-2024
01-2025: 0.9%● unchanged vs 12-2024
02-2025: 0.9%● unchanged vs 01-2025
03-2025: 0.9%● unchanged vs 02-2025
04-2025: 1.7%▲ +0.8 percentage points vs 03-2025
05-2025: 1.8%▲ +0.1 percentage points vs 04-2025highest value
06-2025: 1.7%▼ -0.1 percentage points vs 05-2025
07-2025: 1.7%● unchanged vs 06-2025
08-2025: 0.7%▼ -1.0 percentage point vs 07-2025
09-2025: 0.7%● unchanged vs 08-2025
10-2025: 0.7%● unchanged vs 09-2025
11-2025: 0.7%● unchanged vs 10-2025
12-2025: 0.7%● unchanged vs 11-2025
01-2026: 0.7%● unchanged vs 12-2025
02-2026: 0.7%● unchanged vs 01-2026
03-2026: 0.7%● unchanged vs 02-2026
04-2026: 0.7%● unchanged vs 03-2026
05-2026: 0.8%▲ +0.1 percentage points vs 04-2026
06-2026: 0.8%● unchanged vs 05-2026
07-2026: 0.8%● unchanged vs 06-2026
08-2026: 0.6%▼ -0.2 percentage points vs 07-2026lowest value
09-2026: 0.6%● unchanged vs 08-2026lowest value
10-2026: 0.6%● unchanged vs 09-2026lowest value
Credit of up to €12,000 on 30-day terms is acceptable
Liquidity ample (current ratio 2.82, compared with 2.95 in 2024, above the usual 1.5; short-term debt: 27.6% and cash: 28.4% of total assets), and 29% of the assets are financed with debt and provisions.
How it is calculated
The band follows from the bankruptcy probability, on a scale where 10 more points roughly halve it:
| 75-100 | Excellent | under 0.55% |
| 60-74 | Healthy | 0.55% to 1.5% |
| 45-59 | Fair | 1.5% to 4.2% |
| 25-44 | Weak | 4.2% to 15.0% |
| 0-24 | Critical | over 15.0% |
Where the company stands within its band depends half on the bankruptcy probability and half on how it does against its sector peers (NACE 32, micro): better than 76% on solvency, 74% on liquidity, 18% on profitability and 24% on growth.
The bankruptcy probability was computed on 31-10-2026 by the bankruptcy model of 2 October 2026, which learns from Belgian bankruptcies and reads the registers, the annual accounts and the Belgian Official Gazette.
Some facts cap the score, however low the probability. Negative or zero equity, a heavy loss, a special status in the KBO, one missing filing or accounts filed more than 90 days late hold it at Fair at most (59); two missing filings, at Weak (44). An ongoing judicial reorganisation or the company's end (bankruptcy, dissolution, liquidation) holds it at Critical at most (24).
Credit check for your own amount and term
Show the recommended maximum and see how the verdict changes with amount, term and advance.
Signals
Five signals.
lowers riskraises riskneutral
neutral · Latest accounts filed on time
The financial year that closed on 31-12-2025 was due by 31-07-2026 and was filed on 13-07-2026, 18 days ahead of the deadline.
NBB · 8 filingsDeviation from the deadline
2025
18 days early
2024
3 days early
2023
61 days late
2022
67 days late
2021
3 days early
2020
31 days late
2019
13 days late
← before the deadline
after the deadline →
tick = median of all Belgian filingsring = median in the sector
This company filed its last 7 accounts on average 21 days after the deadline; the sector median (NACE 32) for financial year 2024 is 2 days before the deadline, and 39% of those companies filed late.
Searched, nothing found (2)
neutral · Next filing not due yet
The next financial year closes on 31-12-2026 and is due by 31-07-2027. Nothing is late today. The company usually files around 28 July (4 of the last 5 filed years within 65 days of that day).
Companies Code · seven monthsWhere today falls in the filing period
01-11-2026 today31-12-2026 year end31-07-2027 deadline
Financials · financial year 2025, abbreviated format
Latest annual accounts filed
Annual accounts 2025
- Financial year ended
- 31-12-2025
- Filed on
- 13-07-2026
- Format
- abbreviated format
- Reference
- 2026-00284044
Turnover
≈ €320,000
Estimated: probably between €190,000 and €600,000
Total assets
€242,768▼ 8.9%
2024 · €266,464
Net result
-€29,476
2024 · €26,767
Working capital
€121,770▲ 0.1%
2024 · €121,661
Trend over the years
2021 to 2025, 5 financial years 2018 to 2025, 8 financial years
The operating result turns negative in 2025: a loss of €29,636 after €33,364 in 2024.
What the company sold each financial year and what was left of it. A loss stands below the zero line.
Operating result-€29,636
2025
Net result-€29,476
2025
What the company owns (total assets), how much of it is its own (equity) and how much it owes.
Total assets€242,768
2025
Equity€172,478
2025
Debt€70,290
2025
Short-term assets minus short-term debts. Above zero the company can pay its bills in the short term.
Working capital€121,770
2025
How much of each euro of turnover is left from operations (EBIT margin) and what the assets earn (return on assets).
Return on assets (ROA)-12.1%
2025
The share of the company financed with its own means. The higher it is, the better it absorbs a shock.
Solvency71.0%
2025
Short-term assets per euro of short-term debt. Above 1 the short-term debts are covered.
Current ratio2.82
2025
Average staff in full-time equivalents (FTE).
Staff (FTE)2
2025
Use the arrow keys on the chart for the figures per year.
Sector: the middle half of NACE 32, Other manufacturing: a quarter of companies sit below it, a quarter above. Each year compared with accounts in the same format, and only where there are at least 30. Dashed line: the median. Available for Net result, Equity, Total assets, Working capital, Solvency, Current ratio, Return on assets (ROA), Staff (FTE).
Every figure with its change against the financial year before
favourable
unfavourable
Line20182019202020212022202320242025
Operating result-€112,435-€36,795-€161,556€207,594-€259,510€159,105€33,364▼ 79.0%-€29,636
Net result-€111,863-€36,386-€160,298below the sector's middle half€207,877above the sector's middle half-€240,698below the sector's middle half€119,212above the sector's middle half€26,767within the sector's middle half▼ 77.5%-€29,476below the sector's middle half
Equity€208,137-€249,094▲ 19.7%€88,796within the sector's middle half▼ 64.4%€296,673above the sector's middle half▲ 234%€55,975within the sector's middle half▼ 81.1%€175,187above the sector's middle half▲ 213%€201,954above the sector's middle half▲ 15.3%€172,478within the sector's middle half▼ 14.6%
Total assets€846,367-€784,475▼ 7.3%€613,771above the sector's middle half▼ 21.8%€811,635above the sector's middle half▲ 32.2%€440,782above the sector's middle half▼ 45.7%€306,488within the sector's middle half▼ 30.5%€266,464within the sector's middle half▼ 13.1%€242,768below the sector's middle half▼ 8.9%
Debt€638,230-€535,381▼ 16.1%€524,975▼ 1.9%€514,963▼ 1.9%€384,807▼ 25.3%€131,301▼ 65.9%€64,510▼ 50.9%€70,290▲ 9.0%
Working capital-€24,053-€24,601-€112,479below the sector's middle half€130,304above the sector's middle half-€81,502below the sector's middle half€66,668within the sector's middle half€121,661above the sector's middle half▲ 82.5%€121,770within the sector's middle half▲ 0.1%
Solvency24.6%-31.8%▲ 7.2pp14.5%below the sector's middle half▼ 17.3pp36.6%within the sector's middle half▲ 22.1pp12.7%below the sector's middle half▼ 23.9pp57.2%within the sector's middle half▲ 44.5pp75.8%above the sector's middle half▲ 18.6pp71.0%above the sector's middle half▼ 4.7pp
Current ratio0.96-1.05▲ 0.080.78below the sector's middle half▼ 0.261.26within the sector's middle half▲ 0.470.79below the sector's middle half▼ 0.471.53within the sector's middle half▲ 0.742.95within the sector's middle half▲ 1.422.82within the sector's middle half▼ 0.13
Return on assets (ROA)-13.2%-4.6%▲ 17.9pp-26.1%below the sector's middle half▼ 30.8pp25.6%above the sector's middle half▲ 51.7pp-54.6%below the sector's middle half▼ 80.2pp38.9%above the sector's middle half▲ 93.5pp10.0%within the sector's middle half▼ 28.9pp-12.1%below the sector's middle half▼ 22.2pp
Staff (FTE)2.7-1.6▼ 40.7%1.7within the sector's middle half▲ 6.3%2.1▲ 23.5%22=2within the sector's middle half=
above
within
below
the middle half of NACE 32, Other manufacturing: a quarter of companies sit below it, a quarter above. Each year compared with accounts in the same format, and only where there are at least 30.
Turnover and EBIT margin not published: the abbreviated or micro format does not require them. The turnover shown is an estimate from the gross margin.
Balance-sheet composition
2025 in colour, 2024 as the grey bar beneath
Assets €242,768
Fixed assets
€53,919 ▼ 34.6%
Current assets
€188,849 ▲ 2.6%
Equity and liabilities €242,768
Equity
€172,478 ▼ 14.6%
Debt
€70,290 ▲ 9.0%
Debt's share of the balance-sheet total rises from 24.2% to 29.0%. Equity is lower and debt is higher.
Key figures and ratios
EBITDA
€4,228▼
2024 · €69,615
Cash flow
€4,388▼
2024 · €63,018
Quick ratio
2.53▲
2024 · 2.46
Debt to equity
0.41▲
2024 · 0.32
ROE
-17.1%▼
2024 · 13.3%
Interest coverage
1.25▼
2024 · 9.58
Debt ≤ 1 year
€67,079▲
2024 · €62,396
Debt > 1 year
€3,211▲
2024 · €2,114
Staff costs
€117,775▲
2024 · €85,510
Green means a favourable move, even when the figure itself falls: as with debt or debt to equity.
Peer companies
Historical observationOf the 3,591 companies that looked in July 2024 the way this one looks now, 3.0% went bankrupt within 24 months and 87.4% are still going.
- Micro
- 5 to 10 years old
- solvency 30% or more
- a loss of 10% of the balance sheet or more
3.0%
went bankrupt
9.4%
stopped otherwise
87.4%
still going
A further 0.2% stopped, but we cannot tell whether within those 24 months.
For this company itself Checked computes a bankruptcy probability of 0.6% over twelve months; the group does not contradict it.
How reliable is this rule?
Tested on the year before, without using that year itself: the groups of July 2023 gave each of the 497,445 companies of July 2024 its group's bankruptcy share. Expected: 1.6%; actually bankrupt within 24 months: 1.7%.
| Group | Expected | Actual |
|---|---|---|
| 1 | 0.2% | 0.2% |
| 2 | 0.3% | 0.5% |
| 3 | 0.5% | 0.6% |
| 4 | 0.7% | 0.8% |
| 5 | 0.9% | 0.9% |
| 6 | 1.3% | 1.5% |
| 7 | 1.6% | 1.8% |
| 8 | 1.8% | 1.8% |
| 9 | 3.0% | 3.1% |
| 10 | 5.6% | 6.2% |
The rule ranks well: a company that went bankrupt got a higher share than one that kept going in 74.5% of comparisons. The level follows the economy: in a year with more bankruptcies, the actual share is higher than the year before.
An observation about 3,591 comparable companies, not a prediction for this company. The sector does not count: the register keeps no sector for companies that stopped, so it would make the outcome look better than it was.
Annual accounts
| Line | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Change |
|---|---|---|---|---|---|---|---|---|---|
| Remuneration, social security and pensions62 | - | - | - | €94,855 | €94,879 | €116,636 | €85,510 | €117,775 | ▲ 37.7% |
| Depreciation of and write-downs on formation expenses, intangible and tangible fixed assets630 | €44,784 | €32,302 | €35,950 | €36,773 | €35,927 | €35,660 | €36,251 | €33,864 | ▼ 6.6% |
| Other operating charges640/8 | - | - | - | €4,721 | €2,745 | €7,534 | €8,836 | €3,446 | ▼ 61.0% |
| Gross operating margin9900 | €153,580 | €137,496 | -€44,466 | €343,943 | -€125,959 | €318,935 | €163,961 | €125,449 | ▼ 23.5% |
| Operating profit (loss)9901 | -€112,435 | €36,795 | -€161,556 | €207,594 | -€259,510 | €159,105 | €33,364 | -€29,636 | - |
| Financial income75/76B | - | - | - | €1,871 | €19,515 | €3,248 | €671 | €3,530 | ▲ 426% |
| Recurring financial income75 | €1,230 | €959 | €1,822 | €1,871 | €11,609 | €417 | €671 | €1,065 | ▲ 58.7% |
| Non-recurring financial income76B | - | - | - | - | €7,906 | €2,831 | - | €2,465 | - |
| Financial charges65/66B | - | - | - | €1,407 | €351 | €43,141 | €7,268 | €3,370 | ▼ 53.6% |
| Recurring financial charges65 | €529 | €1,368 | €565 | €1,407 | €351 | €2,793 | €7,268 | €3,370 | ▼ 53.6% |
| Non-recurring financial charges66B | - | - | - | - | - | €40,348 | - | - | - |
| Profit (loss) for the period before taxes9903 | -€111,734 | €36,386 | -€160,298 | €208,058 | -€240,346 | €119,212 | €26,767 | -€29,476 | - |
| Income taxes67/77 | €129 | - | - | €181 | €352 | - | - | - | - |
| Profit (loss) for the period9904 | -€111,863 | €36,386 | -€160,298 | €207,877 | -€240,698 | €119,212 | €26,767 | -€29,476 | - |
| Profit (loss) for the period to be appropriated9905 | -€111,863 | €36,386 | -€160,298 | €207,877 | -€240,698 | €119,212 | €26,767 | -€29,476 | - |
| Line | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Change |
|---|---|---|---|---|---|---|---|---|---|
| Assets | |||||||||
| Total assets20/58 | €846,367 | €784,475 | €613,771 | €811,635 | €440,782 | €306,488 | €266,464 | €242,768 | ▼ 8.9% |
| Fixed assets21/28 | €244,368 | €229,293 | €208,912 | €173,404 | €137,477 | €114,692 | €82,407 | €53,919 | ▼ 34.6% |
| Intangible fixed assets21 | €826 | €454 | €83 | - | - | - | - | - | - |
| Tangible fixed assets22/27 | €243,543 | €228,838 | €208,830 | €173,404 | €137,477 | €114,692 | €82,407 | €53,919 | ▼ 34.6% |
| Plant, machinery and equipment23 | - | - | - | €162,167 | €129,787 | €110,116 | €78,084 | €47,355 | ▼ 39.4% |
| Furniture and vehicles24 | - | - | - | €11,236 | €7,689 | €4,576 | €4,323 | €6,564 | ▲ 51.8% |
| Current assets29/58 | €601,999 | €555,183 | €404,859 | €638,232 | €303,305 | €191,796 | €184,057 | €188,849 | ▲ 2.6% |
| Amounts receivable after more than one year29 | - | - | - | €52,779 | - | - | - | - | - |
| Other amounts receivable291 | - | - | - | €52,779 | - | - | - | - | - |
| Stocks and contracts in progress3 | €19,921 | €47,173 | €96,629 | €64,240 | €87,592 | €41,187 | €30,428 | €19,021 | ▼ 37.5% |
| Stocks30/36 | - | - | - | €64,240 | €87,592 | €41,187 | €30,428 | €19,021 | ▼ 37.5% |
| Amounts receivable within one year40/41 | €96,558 | €244,279 | €155,024 | €369,950 | €176,772 | €127,408 | €112,240 | €90,986 | ▼ 18.9% |
| Trade receivables40 | - | - | - | €328,098 | €70,773 | €78,047 | €78,035 | €55,735 | ▼ 28.6% |
| Other amounts receivable41 | - | - | - | €41,852 | €105,999 | €49,361 | €34,205 | €35,251 | ▲ 3.1% |
| Current investments50/53 | - | - | - | - | €38,941 | - | - | - | - |
| Cash at bank and in hand54/58 | €182,408 | €172,432 | €83,801 | €144,215 | - | €23,201 | €41,389 | €68,841 | ▲ 66.3% |
| Deferred charges and accrued income490/1 | - | - | - | €7,048 | - | - | - | €10,001 | - |
| Equity and liabilities | |||||||||
| Total equity and liabilities10/49 | €846,367 | €784,475 | €613,771 | €811,635 | €440,782 | €306,488 | €266,464 | €242,768 | ▼ 8.9% |
| Equity10/15 | €208,137 | €249,094 | €88,796 | €296,673 | €55,975 | €175,187 | €201,954 | €172,478 | ▼ 14.6% |
| Contributions10/11 | €320,000 | €320,000 | €320,000 | €320,000 | €320,000 | €320,000 | €320,000 | €320,000 | = |
| Capital10 | - | - | - | €320,000 | - | €320,000 | €320,000 | €320,000 | = |
| Issued capital100 | - | - | - | €320,000 | - | €320,000 | €320,000 | €320,000 | = |
| Profit (loss) carried forward14 | -€111,863 | -€70,906 | -€231,204 | -€23,327 | -€264,025 | -€144,813 | -€118,046 | -€147,522 | ▼ 25.0% |
| Amounts payable17/49 | €638,230 | €535,381 | €524,975 | €514,963 | €384,807 | €131,301 | €64,510 | €70,290 | ▲ 9.0% |
| Amounts payable after more than one year17 | €1,500 | €4,800 | €7,637 | €5,758 | - | €6,173 | €2,114 | €3,211 | ▲ 51.9% |
| Financial debts170/4 | - | - | - | €958 | - | €6,173 | €2,114 | €3,211 | ▲ 51.9% |
| Other amounts payable178/9 | - | - | - | €4,800 | - | - | - | - | - |
| Amounts payable within one year42/48 | €626,052 | €530,581 | €517,337 | €507,927 | €384,807 | €125,128 | €62,396 | €67,079 | ▲ 7.5% |
| Current portion of amounts payable after more than one year42 | - | - | - | €1,880 | €958 | - | - | - | - |
| Financial debts43 | - | - | - | - | - | €53,843 | €4,059 | €4,058 | = |
| Credit institutions430/8 | - | - | - | - | - | €53,843 | €4,059 | €4,058 | = |
| Trade debts44 | €14,168 | €36,753 | €68,552 | €84,856 | €40,365 | €25,347 | €22,349 | €16,660 | ▼ 25.5% |
| Suppliers440/4 | - | - | - | €84,856 | €40,365 | €25,347 | €22,349 | €16,660 | ▼ 25.5% |
| Advances received on contracts in progress46 | - | - | - | €412,002 | €307,002 | - | - | - | - |
| Taxes, remuneration and social security45 | - | - | - | €8,453 | €10,549 | €18,826 | €8,193 | €9,134 | ▲ 11.5% |
| Taxes450/3 | - | - | - | €3,426 | €534 | €352 | - | - | - |
| Remuneration and social security454/9 | - | - | - | €5,028 | €10,016 | €18,474 | €8,193 | €9,134 | ▲ 11.5% |
| Other amounts payable47/48 | - | - | - | €737 | €25,933 | €27,112 | €27,795 | €37,227 | ▲ 33.9% |
| Accrued charges and deferred income492/3 | - | - | - | €1,277 | - | - | - | - | - |
| Line | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Change |
|---|---|---|---|---|---|---|---|---|---|
| Profit (loss) for the period9904 | -€111,863 | €36,386 | -€160,298 | €207,877 | -€240,698 | €119,212 | €26,767 | -€29,476 | - |
| + Depreciation and write-downs630 | €44,784 | €32,302 | €35,950 | €36,773 | €35,927 | €35,660 | €36,251 | €33,864 | ▼ 6.6% |
| Operating cash flow (approximation) | -€67,079 | €68,689 | -€124,347 | €244,650 | -€204,771 | €154,872 | €63,018 | €4,388 | ▼ 93.0% |
| Investment in fixed assets (approximation) | - | -€17,226 | -€15,570 | -€1,265 | €0 | -€12,875 | -€3,966 | -€5,376 | ▼ 35.6% |
| Change in cash | - | -€9,976 | -€88,631 | €60,414 | - | - | €18,188 | €27,452 | ▲ 50.9% |
Simplified and derived: a Belgian filing has no cash-flow statement, so these rows come from the income statement and the balance-sheet moves.
Filings with the National Bank (8)
| Financial year | Type | Filed | Reference | Document |
|---|---|---|---|---|
| 31-12-2025 | abbreviated format | 13-07-2026 | 2026-00284044 | NBB |
| 31-12-2024 | micro format | 28-07-2025 | 2025-00315506 | |
| 31-12-2023 | micro format | 30-09-2024 | 2024-00479576 | |
| 31-12-2022 | micro format | 06-10-2023 | 2023-00477427 | |
| 31-12-2021 | micro format | 28-07-2022 | 2022-20236299 | |
| 31-12-2020 | micro format | 31-08-2021 | 2021-62400513 | |
| 31-12-2019 | micro format | 13-08-2020 | 2020-40900541 | |
| 31-12-2018 | micro format | 26-07-2019 | 2019-38400047 |
Similar companies · same sector, comparable size
Optiek Ineke
BE 0679.685.433
Hove · equity €172,453
Shoe Consult Niels Robben
BE 0780.820.207
Zonhoven · equity €172,193
TIEBERCO
BE 0432.547.843
Eeklo · equity €173,089
BELGIAN DENTAL LABORATORY SERVICES
BE 0449.254.312
Oostende · equity €173,199
DE VOETZAAK
BE 0834.580.773
Brugge · equity €174,247
Of the 1,235 active companies whose main activity is manufacture of medical and dental instruments and supplies (NACE 32500), figures are known for 700. 548 are within a factor 10 of this equity. These 5 are the closest to it. See the whole sector
Public contracts: No European public contracts awarded found since October 2016. Contracts below the EU thresholds are not in TED.
Directors
Directors
3 directors, 1 in day-to-day management, last change in 2025
Board 3
BUTTIENS Magda Jeanne Josée
Current
Director · in office according to the act of 04-03-2025
JANSSENS Jacques Philibert
Current
Director · in office according to the act of 04-03-2025
JANSSENS Johan
Current
Director · in office according to the act of 04-03-2025
Day-to-day management 1
JANSSENS Jacques Philibert
Current
Managing director · appointed in the act of 04-03-2025
Mandate history
3 people, 3 in office
- Board
- Day-to-day management
- began earlier
| Name | Functions and periods |
|---|---|
| BUTTIENS Magda Jeanne Josée |
|
| JANSSENS Jacques Philibert |
|
| JANSSENS Johan |
|
How the board is organised
Who represents it, and how
- Who signsWho may bind the company towards others, for example by signing a contract.
- Two directors jointly, or a managing director alone
- Board ruleHow the board is made up, meets and takes decisions.
- “3, algemene vergadering”“Raad kiest uit zijn midden een voorzitter, andere bestuurder aangeduid door collega’s”“Voorzitter of indien verhinderd ondervoorzitter of bij gebrek andere bestuurder aangeduid door collega’s, telkens belang vennootschap…”
Oversight and winding up
- Liquidation ruleHow assets are shared after dissolution: creditors first, then shareholders.
- “Benoeming van de vereffenaars, bestuursorgaan in functie als college”1 more provision on this in the deed
Articles of association, deed of 04-03-2025
Owners and capital
Owners
1 ownerChain of control
- Dokter Janssens Jacques
- BIONCISE
Owners 1
-
67.67%
Capital and shareholders
Shareholders according to the deeds
Stated in the act
act of 04-03-2025 ↗
- Dokter Janssens Jacques (BE 0824.062.906) 180 shares
- JANSSENS Jacques Philibert 10 shares
- BUTTIENS Magda Jeanne Josée 10 shares
- GUTIERREZ MILLIET Enrique Alejandro 53 shares
- GUTIERREZ LEMA Enrique Antonio 13 shares
Capital over the years
- 04-03-2025 Capital stated in the deed · €320,000 · 266 shares
Shares according to the articles of association
- Transfer restrictionWhether shareholders may sell their shares freely or need approval first.
- “Vraag tot goedkeuring, overdracht en overgang aan natuurlijke persoon of rechtspersoon”
- Other provisionsRules from the articles on subjects other than the board, the shares, the purpose and the meetings.
- Other provision: “Mag worden verhoogd of verlaagd door besluit van de algemene vergadering die beraadslaagt volgens de regels gesteld voor de wijziging van de…”Other provision: “Tenminste vijftien dagen te rekenen van dag van openstelling van intekening, bij kapitaalverhoging, uitgifte van converteerbare obligaties…”Other provision: “Opvraging van stortingen, recht nog verschuldigd saldo en schadevergoeding te eisen”Other provision: “Op naam, aard van de aandelen”Other provision: “Op naam, alle andere effecten dan aandelen”Other provision: “Ondeelbaarheid van de aandelen, rechten uitgeoefend door vruchtgebruiker”Other provision: “Elke bestuurder aan één collega voor bepaalde raad, besluitvorming raad van bestuur”Other provision: “Notulen raad van bestuur, bijzonder register”Other provision: “Alle handelingen nodig of dienstig tot verwezenlijking voorwerp, bevoegdheden raad van bestuur”Other provision: “Raad bepaalt alleen of gezamenlijk, dagelijks bestuur”Other provision: “Vergoeding bestuurders, of en in welke mate mandaat bezoldigd met vaste of variabele vergoeding”Other provision: “Financiële toestand, jaarrekening, regelmatigheid weer te geven verrichtingen, controle vennootschap”Other provision: “Toelating algemene vergadering, indien enkel stemrechten geschorst nog deelnemen zonder stemming”Other provision: “Elke eigenaar van effecten, gevolmachtigde al dan niet aandeelhouder”Other provision: “Voorzitter raad van bestuur, bij ontstentenis ondervoorzitter, bij gebrek andere bestuurder aangewezen door collega’s, samenstelling bureau”Other provision: “Niet over niet-geagendeerde onderwerpen, beraadslaging algemene vergadering”Other provision: “Eenparig schriftelijk alle besluiten binnen wettelijke grenzen behalve bij authentieke akte, schriftelijke algemene vergadering”Other provision: “Stemrecht, 29”Other provision: “Jaarlijkse,buitengewone en bijzondere, verdaging algemene vergadering”Other provision: “Notulen algemene vergadering, 31”Other provision: “Bestemming van de winst, jaarvergadering”Other provision: “Uitkering van dividenden en interimdividenden, voor einde boekjaar van vaststelling”Other provision: “Rechtbanken van de zetel, geschillen”3 more provisions in the deed, see the deed of 04-03-2025
Articles of association, deed of 04-03-2025 (in Dutch)
Group and network
Connections & network
3 current directorsThe network starts from this company’s directors. Other companies they run appear here as nodes.
This company
Company
Director
Shareholding
+N: links not shown yet
Click a node to look further, drag to arrange, zoom with the mouse wheel.
History
Acts, filings and financial milestones
Next filing, financial year 2026, expected by
2026
13-07
financial year 2025 · abbreviated format
2025
28-07
financial year 2024 · micro format
04-03
Gazette deed
Reappointments: JANSSENS Jacques Philibert, BUTTIENS Magda Jeanne Josée and JANSSENS JohanAppointment: JANSSENS Jacques Philibert (managing director) · Shareholding · Amendment of the articles22 facts ▸
Gazette deed
Reappointments: JANSSENS Jacques Philibert, BUTTIENS Magda Jeanne Josée and JANSSENS Johan
Appointment: JANSSENS Jacques Philibert (managing director) · Shareholding · Amendment of the articles22 facts ▸
- General meeting, 27-02-2025
- Shareholding, “A”, 180 (deed in Dutch)
- Shareholding, “A”, 10 (deed in Dutch) (2 times)
- Shareholding, “A”, 53 (deed in Dutch)
- Shareholding, “A”, 13 (deed in Dutch)
- Other provision, “A, uitgegeven en vertegenwoordigde aandelen” (deed in Dutch)
- Other provision, “schorsing lidmaatschapsrechten wegens niet-volstorting, lidmaatschapsrechten waaronder uitoefening van het stemrecht” (deed in Dutch)
- Other provision, “A, stemgerechtigde deelneming aan vergadering” (deed in Dutch)
- Board composition, JANSSENS Jacques Philibert (director)
- Board composition, BUTTIENS Magda Jeanne Josée (director)
- Board composition, JANSSENS Johan (director)
- Other provision, “onderhands schrijven, verzaking oproepingsformaliteiten” (deed in Dutch)
- +10 further facts in this act
2024
31-12
Financial
Equity above €200,000equity €201,954 ▲15.3%
2 profitable years in a row build equity to €201,954.
30-09
financial year 2023 · micro format · 61 days late
2023
31-12
Financial
Back to profitnet €119,212
Net result €119,212 after one loss-making year.
31-12
Financial
Equity above €150,000equity €175,187 ▲213%
Equity rises from €55,975 to €175,187.
06-10
financial year 2022 · micro format · 67 days late
2022
31-12
Financial
Weakest financial yearnet -€240,698
Net result drops to -€240,698, the lowest in the series; recovery starts the following year.
28-07
financial year 2021 · micro format
2021
31-12
Financial
Back to profitnet €207,877
Net result €207,877 after one loss-making year.
31-12
Financial
Equity above €200,000equity €296,673 ▲234%
Equity rises from €88,796 to €296,673.
Show earlier events
31-08
financial year 2020 · micro format · 31 days late
2020
13-08
financial year 2019 · micro format · 13 days late
2019
31-12
Financial
Back to profitnet €36,386
Net result €36,386 after one loss-making year.
26-07
financial year 2018 · micro format
Financial milestoneGazette deedNBB filingFinancial milestones sit on the financial year-end date, not the filing date.
Sources:Publications in the Belgian Official GazetteFilings with the National Bank
Register details
Who it is
KBO recordName
BIONCISE in Dutch
Enterprise number
0671.983.435
Legal form
Public limited company
Status
Active, normale toestand
Founded
02-03-2017
Type
Legal entity
Where it is based
Registered office
Bodemstraat 16, 3830 Wellen, Belgium
Establishments
1 establishment unit since 2017
What it does
NACEBEL 202532500
Manufacture of medical and dental instruments and supplies main activity
46460
Wholesale of pharmaceutical and medical goods
47741
Retail sale of medical and orthopaedic goods, excluding prescription glasses and lenses
47750
Retail sale of cosmetics and toilet articles
Invoicing and payment
VAT number
BE 0671.983.435
Financial year and general meeting
Accounts at the NBBFinancial year end
31-12
Scores and ratios are computed by Checked and are not a credit decision.
Purpose, financial year and meetings according to the articles of association
What the company does
- PurposeThe activities the company may carry out under its articles.
- “De uitbating zowel in eigen beheer als aan derden uitbesteed van: de groot- en kleinhandel, de in-en uitvoer, de ontwikkeling, de promotie…”
6 activities
- De uitbating zowel in eigen beheer als aan derden uitbesteed van: de groot- en kleinhandel, de in-en uitvoer, de ontwikkeling, de promotie en de vervaardiging, de commissiehandel van medische artikelen, farmaceutische producten, apparatuur gebruikt in de geneeskunde
- De verwerving van octrooien en licenties
- Groot- en kleinhandel, in- en uitvoer, ontwikkeling, promotie, vervaardiging, commissiehandel in: biopsie-systemen en materialen; medisch – chirurgisch materiaal, instrumenten en benodigdheden; parfums en cosmetica; toiletartikelen, lichaams- en haarverzorgingsproducten
- Verstrekken van diensten op het vlak van regulering (regulatory affairs) in het kader van medische hulpmiddelen
- Dienstverlening bij procedures voor het opstellen, controleren en indienen van autorisatie-aanvragen
- Ondersteuning bij het beheer en levenscyclusmanagement van medische producten
- DurationHow long the company exists; usually unlimited, so until it is dissolved.
- Unlimited
- Name clauseThe name the company operates under according to its articles.
- BIONCISE
- Registered office clauseThe region of the registered office; it decides among other things the language of official documents.
- “Vlaamse Gewest, Artikel 2. Zetel”
Meetings and financial year
- Annual meetingWhen the shareholders meet each year, among other things to approve the annual accounts.
- Third Friday of June at 21:00
Articles of association, deed of 04-03-2025 (in Dutch)
Environmental permits: No permit applications found in Flanders.
Sites & property
Registered office and establishments
1 establishment unit
Bodemstraat 16, 3830 Wellen
since 2017unit no. 2.262.452.150
Buildings and parcels at the address
Ground area
1.8 ha
Building footprint
3,822 m²
Building volume
29,188 m³
Parcel 73098F0235/00D000, Flanders · tallest building 8.8 m.
1 parcel
Flanders
1
(100%)
| Cadastral parcel | Region | Area | Buildings | Height / floors |
|---|---|---|---|---|
| 73098F0235/00D000 | Flanders | 1.8 ha | 1 · 3,822 m² | 8.8 m · 3 |